Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer

Uterine endometrial cancer is one of the most common gynecological malignancies worldwide. With relatively few options for late-line therapies for advanced or relapsed endometrial cancer, the use of pretreated therapies may broaden the choice of treatments. Here, we report a case of recurrent micros...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimura, Kaito, Shimomura, Akihiko, Gota, Tomoko, Ando, Kenju, Kawamura, Yukino, Taniyama, Tomoko, Oishi, Hajime, Shimizu, Chikako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582696/
https://www.ncbi.nlm.nih.gov/pubmed/36277029
http://dx.doi.org/10.1016/j.gore.2022.101084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582696/
https://www.ncbi.nlm.nih.gov/pubmed/36277029
http://dx.doi.org/10.1016/j.gore.2022.101084

Ejemplares similares